City of Hope Names Michael A. Caligiuri as President of City of Hope National Medical Center

Article

In Partnership With:

City of Hope announced that it has appointed Michael A. Caligiuri, M.D., in a new executive leadership role as president of City of Hope National Medical Center and physician-in-chief.

City of Hope today announced that it has appointed Michael A. Caligiuri, M.D., in a new executive leadership role as president of City of Hope National Medical Center and physician-in-chief. Caligiuri is a health care visionary, world-renowned cancer researcher and president of the American Association for Cancer Research. He will join City of Hope in February 2018.

“This is an extraordinary time in cancer research and care. Every day brings exciting new discoveries and innovations, and City of Hope is at the forefront of groundbreaking work that will define new standards of care,” said Robert W. Stone, City of Hope’s president and chief executive officer. “Dr. Caligiuri is an exceptional and accomplished leader who will join and lead an extraordinary group of talented individuals singularly focused on eradicating cancer and diabetes. As I have come to know him, I have been struck by his innovative approach to science, high degree of humility and dedication to serving patients in need — all of which fit perfectly with City of Hope.”

In this new role, Caligiuri will be responsible for driving innovation into cancer care and delivery. Specifically, he will encourage and develop new paradigms for translating state-of-the-art research into practice at City of Hope, the community and beyond that will further move the institution to the leading edge of cancer treatment and care. He will also be responsible for optimizing the patient care system to ensure the highest quality and safest patient experience.

Most recently, Caligiuri was director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio, leading the institution to remarkable research and clinical achievements. As a physician-scientist, he is well-known for his work in immunology which focuses on human natural killer cells and their modulation for the treatment of leukemia, myeloma and glioblastoma. More than 1,500 cancer patients have been treated on clinical protocols that have emanated from the Caligiuri laboratory.

“City of Hope is an incredible institution with an amazing history of innovation,” Caligiuri said. “I have many friends and colleagues at City of Hope and I am incredibly excited about the organization’s vision. I share that vision and excitement for the role City of Hope will play in changing the global landscape of cancer care.”

“We make this critical appointment at a time when cancer discoveries hold tremendous promise for patients worldwide,” Stone said. “Together, we are committed to being at the center of eliminating cancer and diabetes by bringing tomorrow’s discoveries to the patients who need them today.”

About City of Hope

City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 49 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution.

For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

Related Videos
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Jasmin M. Zain, MD
Richard Kim, MD, an expert on colorectal cancer
A panel of 6 experts on colorectal cancer
Daneng Li, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.